Why Henry Schein (HSIC) Is Getting Attention Now
Henry Schein (HSIC) is reshaping its leadership, with former ITT finance chief Emmanuel Caprais set to become Chief Financial Officer and Senior Vice President, a move that puts governance and capital allocation firmly in focus for shareholders.
Recent trading reflects that investors are still weighing this leadership shift. The share price is US$85.56 after an 11.38% year to date share price return, while the 1 year total shareholder return of 35.27% indicates momentum that has built more gradually over a longer period.
Scan Henry Schein’s leadership reshuffle alongside a curated set of healthcare peers by checking the 34 healthcare AI stocks that could be primed for their own management driven re-rate.
Henry Schein’s shares have already delivered a solid 1-year total return and still trade at a discount to both one estimate of intrinsic value and the average analyst target. Does that skew the risk-reward profile toward buyers, or suggest more hesitation from here?
Most Popular Narrative: 13% Undervalued
Henry Schein’s most followed valuation story puts fair value at $98.19, above the last close of $85.56. This frames the current debate around how much of its margin plan is already in the price.
The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings. It expects over 50% of non-GAAP operating income to come from these segments, supporting structurally higher gross margins and likely driving earnings expansion.
See why 6 investors see Henry Schein as 13% undervalued.
Result: Fair Value of $98.19 (UNDERVALUED)
Still, Henry Schein’s thesis leans heavily on multi year analyst forecasts, and any miss on margin or scanner pricing pressure could quickly reset that optimism.
Find out about the key risks to this Henry Schein narrative.
Next Steps
Sentiment on Henry Schein is mixed, with clear positives and some pointed concerns. Move quickly, review the underlying data, and weigh the 3 key rewards and 1 important warning sign carefully.
Looking for more investment ideas beyond Henry Schein?
Do not stop your research with Henry Schein. Broaden your watchlist with data driven ideas so you are not chasing the same crowded opportunities as everyone else.
- Target resilient compounding potential by reviewing companies that screen as financially strong and conservatively funded through the list of solid balance sheet and fundamentals (25 results).
- Hunt for mispriced quality by scanning the 32 high quality undervalued stocks that combine healthier balance sheets with attractive fundamentals.
- Spot earlier stage potential by checking the 11 elite penny stocks with strong financials that pair stronger financial profiles with higher upside risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com